# Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

> **NCT03907488** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 994 (actual)

## Conditions studied

- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
- Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Lymphocyte-Rich Classic Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Brentuximab Vedotin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin Hydrochloride
- **BIOLOGICAL:** Filgrastim
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pegfilgrastim
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy
- **DRUG:** Vinblastine Sulfate

## Key facts

- **NCT ID:** NCT03907488
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-29
- **Primary completion:** 2024-03-31
- **Final completion:** 2027-03-28
- **Target enrollment:** 994 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03907488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03907488, "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03907488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*